Sprimeo

RSS

Withdrawn

This medicine's authorisation has been withdrawn

aliskiren
MedicineHumanWithdrawn

Latvian is available via eTranslation, the European Commission's machine translation service.

Translate to Latvian | Important information about machine translation

  • Application under evaluation
  • CHMP opinion
  • European Commission decision

Overview

On 22 August 2007 the European Commission issued a marketing authorisation valid throughout the European Union for the medicinal product Sprimeo (aliskiren). Sprimeo was approved for the treatment of essential hypertension. The marketing authorisation holder (MAH) responsible for Sprimeo was Novartis Europharm Ltd. 

The European Commission was notified by letter dated 10 June 2012 of the MAH’s decision to voluntarily withdraw the marketing authorisation for Sprimeo for commercial reasons. On 4 July 2012 the European Commission issued a decision to withdraw the marketing authorisation for Sprimeo. 

Pursuant to this decision the European Public Assessment Report for Sprimeo is updated to reflect the fact that the marketing authorisation is no longer valid.

български (BG) (342.15 KB - PDF)

Skatīt

español (ES) (259.26 KB - PDF)

Skatīt

čeština (CS) (311.96 KB - PDF)

Skatīt

dansk (DA) (258.54 KB - PDF)

Skatīt

Deutsch (DE) (260.03 KB - PDF)

Skatīt

eesti (ET) (258.16 KB - PDF)

Skatīt

ελληνικά (EL) (347.65 KB - PDF)

Skatīt

français (FR) (319.2 KB - PDF)

Skatīt

italiano (IT) (259.5 KB - PDF)

Skatīt

latviešu (LV) (316.27 KB - PDF)

Skatīt

lietuvių (LT) (282.88 KB - PDF)

Skatīt

magyar (HU) (307.75 KB - PDF)

Skatīt

Malti (MT) (311.55 KB - PDF)

Skatīt

Nederlands (NL) (259.07 KB - PDF)

Skatīt

polski (PL) (372.79 KB - PDF)

Skatīt

português (PT) (335.06 KB - PDF)

Skatīt

română (RO) (282.51 KB - PDF)

Skatīt

slovenčina (SK) (310.95 KB - PDF)

Skatīt

slovenščina (SL) (308.01 KB - PDF)

Skatīt

suomi (FI) (318.25 KB - PDF)

Skatīt

svenska (SV) (319.06 KB - PDF)

Skatīt

Product information

български (BG) (2.32 MB - PDF)

Skatīt

español (ES) (1.03 MB - PDF)

Skatīt

čeština (CS) (1.65 MB - PDF)

Skatīt

dansk (DA) (1.09 MB - PDF)

Skatīt

Deutsch (DE) (1.14 MB - PDF)

Skatīt

eesti (ET) (1.09 MB - PDF)

Skatīt

ελληνικά (EL) (2.29 MB - PDF)

Skatīt

français (FR) (1.15 MB - PDF)

Skatīt

italiano (IT) (1.14 MB - PDF)

Skatīt

latviešu (LV) (1.74 MB - PDF)

Skatīt

lietuvių (LT) (1.06 MB - PDF)

Skatīt

magyar (HU) (1.7 MB - PDF)

Skatīt

Malti (MT) (1.81 MB - PDF)

Skatīt

Nederlands (NL) (1.08 MB - PDF)

Skatīt

polski (PL) (1.73 MB - PDF)

Skatīt

português (PT) (1.02 MB - PDF)

Skatīt

română (RO) (1.07 MB - PDF)

Skatīt

slovenčina (SK) (1.79 MB - PDF)

Skatīt

slovenščina (SL) (1.68 MB - PDF)

Skatīt

suomi (FI) (1.03 MB - PDF)

Skatīt

svenska (SV) (1019.89 KB - PDF)

Skatīt

Íslenska (IS) (1.1 MB - PDF)

Skatīt

norsk (NO) (1.11 MB - PDF)

Skatīt
Latest procedure affecting product information:II/0039
04/07/2012
icon globe

This medicine’s product information is available in all official EU languages.
Select 'available languages' to access the language you need.

 

Product information documents contain:

  • summary of product characteristics (annex I);
  • manufacturing authorisation holder responsible for batch release (annex IIA);
  • conditions of the marketing authorisation (annex IIB);
  • labelling (annex IIIA);
  • package leaflet (annex IIIB).

български (BG) (427.3 KB - PDF)

Skatīt

español (ES) (369.76 KB - PDF)

Skatīt

čeština (CS) (387.75 KB - PDF)

Skatīt

dansk (DA) (344.96 KB - PDF)

Skatīt

Deutsch (DE) (351.03 KB - PDF)

Skatīt

eesti (ET) (348.09 KB - PDF)

Skatīt

ελληνικά (EL) (430.1 KB - PDF)

Skatīt

français (FR) (373.1 KB - PDF)

Skatīt

italiano (IT) (367.54 KB - PDF)

Skatīt

latviešu (LV) (369.95 KB - PDF)

Skatīt

lietuvių (LT) (374.13 KB - PDF)

Skatīt

magyar (HU) (385.82 KB - PDF)

Skatīt

Malti (MT) (389.44 KB - PDF)

Skatīt

Nederlands (NL) (365.63 KB - PDF)

Skatīt

polski (PL) (399.45 KB - PDF)

Skatīt

português (PT) (369.22 KB - PDF)

Skatīt

română (RO) (369.48 KB - PDF)

Skatīt

slovenčina (SK) (390.13 KB - PDF)

Skatīt

slovenščina (SL) (399.01 KB - PDF)

Skatīt

suomi (FI) (344.56 KB - PDF)

Skatīt

svenska (SV) (370.53 KB - PDF)

Skatīt

Íslenska (IS) (367.27 KB - PDF)

Skatīt

norsk (NO) (369.99 KB - PDF)

Skatīt

Product details

Name of medicine
Sprimeo
Active substance
aliskiren
International non-proprietary name (INN) or common name
aliskiren
Therapeutic area (MeSH)
Hypertension
Anatomical therapeutic chemical (ATC) code
C09XA02

Pharmacotherapeutic group

Agents acting on the renin-angiotensin system

Therapeutic indication

Treatment of essential hypertension.

Authorisation details

EMA product number
EMEA/H/C/000851
Marketing authorisation holder
Novartis Europharm Ltd.

Novartis Europharm Limited
Wimblehurst Road
Horsham
West Sussex, RH12 5AB
United Kingdom

Marketing authorisation issued
22/08/2007
Withdrawal of marketing authorisation
04/07/2012
Revision
5

Assessment history

This page was last updated on

Share this page